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Abstract
Background: Oxidative stress (OxS) has recently been linked with osteoporosis; however, we do
not know the influence of OxS as an independent risk factor for this disease.
Methods: We conducted a case-control study in 94 subjects ≥60 years of age, 50 healthy and 44
with osteoporosis. We measured total antioxidant status, plasma lipid peroxides, antioxidant
activity of superoxide dismutase and glutathione peroxidase (GPx), and calculated the SOD/GPx
ratio. Bone mineral density was obtained at the peripheral DXA in calcaneus using a portable
Norland Apollo Densitometer®. Osteoporosis was considered when subjects had a BMD of 2.5
standard deviations or more below the mean value for young adults.
Results: GPx antioxidant activity was significantly lower in the group of subjects with osteoporosis
in comparison with the group of healthy subjects (p < 0.01); in addition, the SOD/GPx ratio was
significantly higher in the group of individuals with osteoporosis (p < 0.05). In logistic regression
analysis, we found OxS to be an independent risk factor for osteoporosis (odds ratio [OR] = 2.79;
95% confidence interval [95% CI] = 1.08–7.23; p = 0.034).
Conclusion: Our findings suggest that OxS is an independent risk factor for osteoporosis linked
to increase of SOD/GPx ratio.
Background
Oxidative stress (OxS) is a biochemical disequilibrium
propitiated by excessive production of free radicals (FR)
and reactive oxygen species (ROS), which provoke oxida-
tive damage to biomolecules and which cannot be coun-
teracted by antioxidative systems. This biochemical
alteration has been linked with aging and more of 100
chronic-degenerative diseases, among which osteoporosis
is found [1,2].
Thus, epidemiologic studies on osteoporosis should con-
sider OxS, in addition to risk factors linked with lifestyles,
hormonal changes, and aging [3-5]. It has been demon-
strated recently that FR intervene in bone resorption, pro-
moting osteoclastic differentiation in such a manner that
bone resorption is increased with OxS [6-8].
Similarly, experimental studies have shown a diminution
in antioxidant activity in patients with osteoporosis
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[9,10]. In this regard, Arjmandi et al. (2002) demon-
strated that administration of vitamin E has a beneficial
effect on bone quality in old rats [11]; nevertheless, the
association between OxS and bone mineral density
(BMD) in humans has scarcely been approached.
In an exploratory study, our investigation group found a
negative correlation between BMD and total antioxidant
status (TAS) linked with serum levels low in glutathione
peroxidase (GPx) [12,13]; notwithstanding this, the influ-
ence of OxS as an independent risk factor is unknown,
considering the contribution of the additional risk factors
linked with lifestyles, age, and sex. Therefore, the objective
of this study was to determine the relationship of OxS as
an independent risk factor for osteoporosis in a popula-
tion of elderly adults.
Methods
Study subjects
We carried out a case-control study in a convenience sam-
ple of 94 subjects ≥ 60 years of age, 50 healthy, 20 men
and 30 women (mean age 67.9 ± 6.5 years) and 44 with
osteoporosis, 19 men and 25 women (mean age 69.7 ±
7.3 years). The subjects were community-dwelling Mes-
tizo Mexican elderly living in Mexico City for 10 years or
more. Informative brochures were distributed in the com-
munity specifying the objectives of the study and admis-
sion criteria.
All the women had intact uterus and the mean age in
which their menopause began is the same between the
two study groups. None of the subjects studied had been
taking antioxidant supplementation (vitamins or miner-
als), hormone replacement therapy or antiosteoporotic
medication for at least 6 months prior to the study, none
had acute or chronic diseases, or was receiving prescrip-
tion medications.
Both groups were well-nourished, Mini Nutritional
Assessment (MNA) score was > 23.5, and caloric intake
was between 2,000 and 2500 kcal per day, and the ali-
mentation had the nutrients requirements (protein, fat,
carbohydrate, vitamins and minerals) between Recom-
mended Dietary Allowance (RDA) measured by 24-h die-
tary recalls and serum albumin > 35 g/L [14,15].
The subjects agreed to participate in the study after giving
their informed consent. The Ethics Committee of the Uni-
versidad Nacional Autónoma de México (UNAM)
Zaragoza Campus approved the research protocol for this
study.
Measurements
The following anthropometric measurements were
obtained: weight, height, body mass index (BMI). It was
considered as overweight when BMI ≥ 27 [16].
Weight was measured while the subject was wearing
underwear and a clinical smock and in a fasted state (after
evacuation). A Torino®  scale (Tecno Lógica, Mexicana,
México, TLM®) was used, calibrated before each weight
measurement. Height was obtained with an aluminum
cursor stadiometer graduated in millimeters. The subject
was barefoot, back, and head in contact with the stadiom-
eter in Frankfurt horizontal plane. BMI was calculated by
dividing weight (in kilograms) by height (in square
meters).
Bone mineral density (BMD) was obtained at the periph-
eral DXA in calcaneus using a portable Norland Apollo
Densitometer®. Osteoporosis was considered when sub-
jects had a BMD of 2.5 standard deviations (SD) or more
below the mean value for young adults (T score, ≥2.5)
[17].
Blood samples were collected after a 12-h fasting period
by venopuncture and placed in vacutainer/siliconized test
tubes containing a separating gel and no additives, and
heparin as anticoagulant agent (Becton-Dickinson, Mex-
ico City, Mexico). Blood samples containing heparin were
analyzed using a hemoglobin test protocol (including
hemoglobin, hematocrit, and leukocyte counts). The fol-
lowing serum quantifications were conducted: glucose;
urea; creatinine; urate; albumin; cholesterol; triglycerides,
and cholesterol high-density lipoproteins (HDL). These
tests were used as screening measurements for diagnosis
of clinically healthy subjects.
Hemoglobin levels were measured by cyanomethahemo-
globin reaction procedure (cut-off points: in males,
12.17–17.26 g/dL, and in females, 11.48–16.25 g/dL).
Hematocrit levels were assessed by microhematocrit pro-
cedure (cut-off points: males, 38–52%, females,
36–51%). Leukocyte count was done using Newbauer
Chamber procedure (cut-off points: 3,500–10, 650/
mm3).
All spectrophotometric tests were determined using an
UV-visible spectrophotometer (Shimadzu, Columbia,
MD, USA). Specifically, glucose levels were measured with
glucose oxidase method (cut-off points: 63–120 mg/dL),
urea levels were measured with Berthelot urease method
(cut-off points: 9.5–47.0 mg/dL), creatinine levels by Jaffe
method without deproteinization (cut-off points: males,
0.3–1.5 mg/dL, females, 0.3–1.3 mg/dL), and urate levels
by uricase colorimetric method (cut-off points: males,
2.9–8.88 mg/dL, females, 2.5–8.7 mg/dL). Albumin levelsBMC Musculoskeletal Disorders 2007, 8:124 http://www.biomedcentral.com/1471-2474/8/124
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were measured by bromocresol green technique
(3.23–4.03 g/dL).
Cholesterol was analyzed using CHOD-PAP technique
(cut-off points: 168–200 mg/dL) and triglycerides by
GPO-Trinder technique (cut-off points: 89–190 mg/dL),
whereas HDL were assessed employing the same tech-
nique for cholesterol after precipitation of low and very-
low lipoproteins using a phosphotungstic acid/magne-
sium chloride solution (cut-off points: 42–77 mg/dL).
All reagents employed in biochemical tests were obtained
from Randox Laboratories, Ltd. (Crumlin, Co, Antrim,
UK); cut-off points for reference values for Mexican eld-
erly persons were determined at the Gerontologic Clinical
Research Laboratory of the Universidad Nacional
Autónoma de México (UNAM) Zaragoza Campus in Mex-
ico City [18].
Blood samples containing heparin were subjected to
plasma total antioxidant status (TAS), activity of red
blood cell (RBC) superoxide dismutase (SOD) and glu-
tathione peroxidase (GPx), and plasma TBARS assay. Arte-
factual formation of TBARS in the samples was prevented
by adding 10 μL of 2-mM butylated hydroxytoluene
(BHT) in ethanol at 95% immediately after centrifuga-
tion.
Total antioxidant status was carried out using ABTS+ (2,2'-
azidodiethylbenzothiazolin sulphanate) radical forma-
tion kinetics (Randox Laboratories, Ltd). The presence of
antioxidants in plasma suppressed the bluish-green stain-
ing of the ABTS+ cation, which was proportional to the
antioxidant concentration level. Kinetics is measured at
600 nm.
The method employs xanthine and xanthine oxidase
(XOD) to generate superoxide radicals, which react with
2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazo-
lium chloride (INT) to form a red formazan dye. SOD
activity was measured by degree of inhibition of the reac-
tion (Randox Laboratories, Ltd). Kinetics was measured at
505 nm.
GPx catalyses oxidation of glutathione (GSH) by cumene
hydroperoxide, in the presence of glutathione reductase
(GR) and NADPH; oxidized glutathione (GSSG) is imme-
diately converted into the reduced form with concomitant
oxidation of NADPH to NADP+. Decrease in absorbance
at 340 nm is measured (Randox Laboratories, Ltd).
We used thiobarbituric acid reacting substances (TBARS)
assay. It was performed as described by Jentzsch et al.
(1996) [19]. In the TBARS assay, one molecule of malond-
ialdehyde (MDA) reacts with two molecules of thiobarbi-
turic acid (TBA) with production of a pink pigment with
absorption at 535 nm. Amplification of peroxidation dur-
ing the assay is prevented by the addition of the chain-
breaking antioxidant BHT. Plasma (400 μL) or MDA
standard (0.2–4 μmol/L) prepared by hydrolysis of
1,1,3,3-tetramethoxypropane (TMP) (Sigma Chemical
Co, St. Louis, MO, USA) was mixed with 400 μL ortho-
phosphoric acid (0.2 mol/L) (Sigma Chemical Co.) and
50 μL BHT (2 mmol/L) (Sigma Chemical Co.) in 12 × 75
mm tubes. Then we added 50 μL TBA reagent (0.11 mol/
L in 0.1 mol/L NaOH) (Fluka Chem., Buchs, Switzerland)
and mixed the contents; subsequently, the contents were
incubated at 90°C for 45 min in a water bath. The tubes
were put on ice to stop the reaction. TBARS were extracted
once with 1000 μL n-butanol (Sigma Chemical Co.). The
upper butanol phase was read at 535 nm and 572 nm to
correct for baseline absorption in UV-visible spectropho-
tometer (Shimadzu, Columbia, MD, USA). MDA equiva-
lents (TBARS) were calculated using the difference in
absorption at two wavelengths and quantification was
done with calibration curve.
The intra- and inter-assay variation coefficients were less
5% in all the determinations.
The within-run precision for the markers were as follows:
LPO by TBARS assay 4.6%; erythrocyte SOD 3.8%; GPx
and TAS with Randox Laboratories 6% and 4.3%, respec-
tively. We calculated SOD/GPx ratio.
Alternative cut-off values for each parameter were defined
on the basis of the 90th percentile of young healthy sub-
jects. A stress score [SS] ranging from 1 to 6 was used, rep-
resenting the severity of biomarkers modifications; a score
1 was given to each value higher or lower than the cut-off.
We categorize subjects as follows according to their scale
in SS: with OxS if SS was > 3, and without OxS if SS was
0–3 [20,21].
Risk factors were measured: sex (female), age (≥ 70 years),
oxidative stress (SS > 3), cigarette smoking (≥ 1 year in the
present), alcohol intake (≥ 2 cups/day) and overweight
(BMI ≥ 27).
Statistical analysis
Data were processed by use of standard statistical software
SPSS 10.0 (SPSS Inc. Chicago, IL, USA). Descriptive statis-
tics are means ± standard deviations (SD). Results were
analyzed using the Student's t-test and linear correlation
analyses. Also were performed odds ratio (OR) of logistic
regression analysis with 95% confidence interval (CI) and
pseudo R-square (R2) [22]. A p-value < 0.05 was consid-
ered significant.BMC Musculoskeletal Disorders 2007, 8:124 http://www.biomedcentral.com/1471-2474/8/124
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Results
Average age, body mass index (BMI), and biochemical
and hematologic parameters did not show statistically sig-
nificant differences between the group of healthy subjects
and that of those with osteoporosis (Table 1). Concerning
OxS biological markers, we found that LPO did not show
differences statistically significant (healthy, 0.258 ± 0.09
vs. osteoporosis, 0.296 ± 0.14 μmol/L; p > 0.05). How-
ever, GPx antioxidant activity was significantly lower in
the group with osteoporosis in comparison with the
healthy group of subjects (healthy, 7,039 ± 2,724 vs. oste-
oporosis, 5,399 ± 2,359 U/L; p < 0.01). Additionally, the
SOD/GPx ratio was significantly higher in the group with
osteoporosis (healthy, 0.028 ± 0.01 vs. osteoporosis,
0.036 ± 0.01; p < 0.05), the remainder of the parameters
not showing significant changes (Table 2).
Similarly, we observed a positive correlation between
BMD with GPx antioxidant activity (r = 0.31; p < 0.01),
TAS (r = 0.20; p < 0.05) and BMI (r = 0.19; p < 0.05), and
a negative correlation with the SOD/GPx ratio (r = -0.30;
p < 0.01). At the same time, there is a negative correlation
between GPx and LPO (r = -0.22; p < 0.05) (Table 3).
Regard risk factors, we found a higher percentage of oste-
oporosis in women, smokers and elderly with OxS, and
lower in overweight individuals (Table 4).
In agreement with the previously mentioned observa-
tions, we found an OxS frequency of 68% in the group of
subjects with osteoporosis in contrast with 38% in
healthy-subject group. In logistic regression analysis, we
found that OxS is an independent risk factor to osteoporo-
sis (OR = 2.79; 95% CI = 1.08–7.23; p = 0.034), while we
similarly observed that sex (female) and age (≥70 years)
are risk factors with OR of 4.47 and 3.45 respectively,
besides the overweight (BMI ≥27) is a protective factor
(OR = 0.36; 95% CI = 0.14–0.93; p < 0.05) (Table 5).
Discussion
Oxidative stress measurement in humans with possibili-
ties of clinical application is at present in a process of tran-
sition. Over the past several years, great advances have
been made in the simplification of reliable diagnostic
tests for evaluating certain OxS biological markers, such as
the measurement of LPO, GPx, SOD, catalase (CAT), total
antioxidant status (TAS), DNA damage, antioxidant vita-
mins (A, C, and E), and minerals (zinc, selenium), among
others [23-25]. Nonetheless, integral clinical interpreta-
tion has been not been considered concerning the param-
eters' abnormal values, taking into consideration that OxS
is a dynamic and complex process.
In this respect, our investigative group has developed a
construct for a more integral measurement of OxS, taking
the different components into consideration [19,20].
According to this construct, in our study we found OxS
frequency to be nearly double in the group of subjects
with osteoporosis compared with that of the healthy-sub-
ject group (osteoporosis, 68% vs. healthy, 38%; p < 0.05),
this congruent with scientific evidence associating OxS
with the etiology and physiopathology of osteoporosis
[2,6,7,9].
Regarding OxS biochemical markers, it has been demon-
strated that subjects with osteoporosis exhibit signifi-
cantly higher LPO [2,6,26]. However, it has also been
reported that there are no significant differences in the
serum levels of subjects with and without osteoporosis in
terms of this biological marker [9]. In our study, we did
not find significatives differences between LPO levels in
the group of subjects with osteoporosis compared with
the healthy-subject group. Inconsistencies in the relation-
ship between LPO and BMD could be due to the biologi-
Table 2: Oxidative stress markers in healthy and osteoporosis 
subjects
Healthy 
(n = 50)
Osteoporosis 
(n = 44)
Lipoperoxides (LPO) (μmol/L) 0.258 ± 0.09 0.296 ± 0.14
Superoxide dismutase (SOD) 
(UI/L)
167 ± 10.7 165 ± 7.4
Glutathione peroxidase (GPx) 
(UI/L)
7039 ± 2724 5399 ± 2359*
Total antioxidant status (TAS) 
(mmol/L)
1.03 ± 0.21 0.96 ± 0.18
SOD/GPx ratio 0.028 ± 0.01 0.036 ± 0.01†
Mean values ± SD; t-test, *p < 0.01, †p < 0.05.
Table 1: Age, body mass index, and biochemical characteristics
Healthy 
(n = 50)
Osteoporosis 
(n = 44)
Age (years) 67.9 ± 6.5 69.7 ± 7.3
Body Mass Index (BMI) (kg/m2) 29.30 ± 3.9 27.85 ± 4.7
Glucose (mg/dL) 103 ± 13.8 94 ± 13.2
Urea (mg/dL) 29 ± 3.9 28 ± 4.7
Creatinine (mg/dL) 0.82 ± 0.26 0.89 ± 0.48
Urate (mg/dL) 5.0 ± 1.6 4.6 ± 1.4
Cholesterol (mg/dL) 222 ± 43 218 ± 53
Triglycerides (mg/dL) 203 ± 102 180 ± 72
HDL (mg/dL) 47 ± 10.5 50 ± 14.7
Albumin (g/dL) 4.3 ± 0.5 4.2 ± 0.5
Hemoglobin (g/dL)
Female 14.8 ± 1.0 14.1 ± 1.1
Male 15.7 ± 1.5 15.8 ± 1.7
Hematocrit (%)
Female 46 ± 2.9 44 ± 3.6
Male 49 ± 4.2 48 ± 5.0
Total leukocytes/mm3 6359 ± 1456 6459 ± 2273
Mean value ± SD (standard deviation), t-test p > 0.05.BMC Musculoskeletal Disorders 2007, 8:124 http://www.biomedcentral.com/1471-2474/8/124
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cal marker applied. In these circumstances, we must
consider that F2-isoprostanes is a better marker than
TBARS, which was applied in our study [2].
Oxidative stress is a dynamic process, and to those sub-
jects having high LPO does not necessarily mean that
these have OxS and vice versa. This because high LPO can
be compensated for by the antioxidant activity of SOD,
GPx, and CAT enzymes, as well as by antioxidant vita-
mins, among other elements involved in OxS; similarly, if
low LPO coexist with very low antioxidant activity, the
subject could have OxS [27-29]. Although
On the other hand, in this work we found that GPx anti-
oxidant activity was significantly lower in the group with
osteoporosis in comparison with the healthy group, in
addition to a positive correlation between GPx and BMD
(r  = 0.31; p  < 0.001), which is consistent with that
reported by other authors [6,9,26]. Nevertheless, we
found no statistically significant differences in SOD anti-
oxidant activity between the groups with and without
osteoporosis, this contrary to that reported by other
authors [6,9], probably due to the previously mentioned
fact that OxS is a dynamic and complex process.
A relevant finding in our study comprised the significantly
higher value of the SOD/GPx ratio in the group of subjects
with osteoporosis. In this respect, the imbalance propiti-
ated by greater SOD activity with respect to GPx favors the
increase in H2O2 levels, and consequently greater OxS
[30,31]. Concerning this, it has been demonstrated that
high H2O2 levels favor the differentiation of osteoblastic
Table 5: Risk factors to osteoporosis
OR CI P value 
Sex (female) 4.47 1.25 – 16.02 0.022
Age (≥ 70 years) 3.45 1.21 – 9.81 0.020
Oxidative stress 2.79 1.08 – 7.23 0.034
Cigarette smoking 3.18 0.62 – 16.29 0.165
Alcohol intake (≥ 2 cups/day) 2.16 0.77 – 6.00 0.140
Overweight (BMI ≥ 27) 0.36 0.14 – 0.93 0.035
Logistic regression, R2 = 0.255, p < 0.01; OR = odds ratio; CI = 
confidence interval
Table 3: Correlation between age, BMI, oxidative stress markers and BMD
T SCORE LPO SOD GPX TAS Age BMI SOD/GPx
r value T SCORE 1.000 -0.090 -0.009 0.316 0.198 -0.111 0.191 -0.309
LPO 1.000 -0.106 -0.219 -0.060 -0.068 0.138 0.099
SOD 1.000 0.006 0.136 -0.021 -0.081 0.061
GPX 1.000 0.205 0.012 0.126 -0.885
TAS 1.000 0.078 0.059 -0.161
Age 1.000 0.077 -0.044
BMI 1.000 -0.241
SOD/GPx 1.000
Sig. (1-tailed) TSCORE 0.215 0.467 0.002 0.039 0.163 0.045 0.003
LPO 0.175 0.025 0.300 0.276 0.111 0.191
SOD 0.478 0.115 0.425 0.236 0.295
GPX 0.034 0.457 0.133 < 0.0001
TAS 0.245 0.300 0.077
Age 0.250 0.351
BMI 0.016
Linear correlation analyses.
Table 4: Frequency of risk factors to osteoporosis by study 
group
Variable Osteoporosis 
(n = 44)
Normal (n = 50)
Gender
Female 36 (82%) 34 (68%)
Male 8 (18%) 16 (32%)
Age
60 – 69 years 21 (48%) 31 (62%)
≥ 70 years 23 (52%) 19 (38%)
Smoke
Positive 6 (14%) 3 (6%)
Negative 38(86%) 47(94%)
Alcohol ingestion
Positive(≥ 2 cups/day) 17 (38%) 13 (26%)
Negative 27 (62%) 37 (74%)
Weight
Overweight (BMI ≥ 27) 23 (52%) 34 (68%)
Normal weight 21 (48%) 16 (32%)
Oxidative stress
Positive 30 (68%)* 19 (38%)
Negative 14 (32%) 31(62%)
*χ2 test, p < 0.01.BMC Musculoskeletal Disorders 2007, 8:124 http://www.biomedcentral.com/1471-2474/8/124
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cells to osteoclasts and inhibit the differentiation of oste-
oblastic cells to osteoblasts, thus propitiating an accentu-
ated diminution of BMD [6-8]. Although, we did not
measure in this study the bone resorption or bone forma-
tion, our findings can be explained though this mecha-
nism.
With respect to risk factors for osteoporosis, some authors
have reported that age (≥70 years), sex (female), low
weight (BMI ≤17), abundant intake of alcoholic beverages
(≥2 drinks per day), smoking, drug intake (glucocorticoid
therapy, aromatase inhibitors, androgen deprivation ther-
apy), and a sedentary lifestyle, among others, are associ-
ated with an increase in the incidence of this disease [32-
35]. In this regard, in our study we found that sex (female)
and age (≥70 years) are significant risk factors for oste-
oporosis, in agreement with what has been reported by
other authors [34,36]. In this regard, it has been pointed
out that premenopausal hormonal decline increases oste-
oporosis incidence in women, and that aging propitiates
bone fragility [37].
On the other hand, overweight (body mass index [BMI] ≥
27) has been reported as a protective factor for osteoporo-
sis [38], which was observed in our study; in this respect,
an increase in the amount of biologically available estro-
gens has been observed, this due to the conversion of
androstenedione into estrone in adipose cells, and a
decrease in the concentration of sex hormone-binding
globulins [39]. Likewise, a positive relationship has also
been found between leptin and bone-specific alkaline
phosphatase in elderly women and men, suggesting that
BMI-linked leptin levels exert an influence on osteoblast
activity in both sexes [40], although no relationship has
been reported between leptin levels and bone mass
[41,42]; thus, the role of leptin on BMD is not clear.
There must be considered as limitations of the study that
BMD was not measured with gold standard" (DXA meas-
urements of the spine or proximal femur), it was used
instead peripheral-calcaneus DXA; nevertheless, several
studies have shown that this method has a 90% sensitivity
and 90% specificity for osteoporosis at the hip or spine
[17,43]. Besides, this study is a cross-sectional and the
sample is not representative; therefore it is necessary to
carry out prospective studies with representatives samples
to confirm our findings.
Conclusion
The most relevant finding of the present study comprised
having found evidence through multivariate analysis that
OxS is an independent risk factor for osteoporosis, sup-
porting the hypothesis that links OxS with the etiology
and physiopathology of this disease. Therefore, the devel-
opment of controlled clinical assays could be justified for
evaluating the usefulness of diets and/or antioxidant sup-
plements in complementary or preventive management
of osteoporosis.
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